These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 19659765)

  • 21. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.
    Kean LS; Turka LA; Blazar BR
    Immunol Rev; 2017 Mar; 276(1):192-212. PubMed ID: 28258702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The therapeutic potential of 4-1BB (CD137) in cancer.
    Nam KO; Kang WJ; Kwon BS; Kim SJ; Lee HW
    Curr Cancer Drug Targets; 2005 Aug; 5(5):357-63. PubMed ID: 16101383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential.
    van de Ven K; Borst J
    Immunotherapy; 2015; 7(6):655-67. PubMed ID: 26098609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming immunosuppressive mechanisms.
    Widén K; Mozaffari F; Choudhury A; Mellstedt H
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii241-7. PubMed ID: 18790959
    [No Abstract]   [Full Text] [Related]  

  • 25. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The promise and challenges of immune agonist antibody development in cancer.
    Mayes PA; Hance KW; Hoos A
    Nat Rev Drug Discov; 2018 Jul; 17(7):509-527. PubMed ID: 29904196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of GITR for cancer immunotherapy.
    Schaer DA; Murphy JT; Wolchok JD
    Curr Opin Immunol; 2012 Apr; 24(2):217-24. PubMed ID: 22245556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential targeting of B7-H4 for the treatment of cancer.
    Podojil JR; Miller SD
    Immunol Rev; 2017 Mar; 276(1):40-51. PubMed ID: 28258701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
    Wolchok JD; Saenger Y
    Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials.
    Egen JG; Ouyang W; Wu LC
    Immunity; 2020 Jan; 52(1):36-54. PubMed ID: 31940272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
    Waight JD; Gombos RB; Wilson NS
    Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibitors for cancer treatment.
    Park J; Kwon M; Shin EC
    Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for anti-GITR cancer immunotherapy.
    Knee DA; Hewes B; Brogdon JL
    Eur J Cancer; 2016 Nov; 67():1-10. PubMed ID: 27591414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New insight into cancer immunotherapy.
    Escribese MM; Barber D
    Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():50-55. PubMed ID: 29108766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.
    Page DB; Yuan J; Wolchok JD
    Immunotherapy; 2010 May; 2(3):367-79. PubMed ID: 20635901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expanding role of immunotherapy.
    Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J
    Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.